Compositions, methods and kits relating to resistin

Abstract

The invention relates to novel nucleic acids encoding a mammalian resistin gene, and proteins encoded thereby, whose expression is suppressed by the antidiabetic compounds thiazolidinediones. The invention further relates to methods of treating and detecting type 2 diabetes and Syndrome X comprising modulating or detecting resistin expression and / or production and activity of resistin polypeptide.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 11 / 590,736, filed Oct. 31, 2006, which is a continuation of U.S. patent application Ser. No. 09 / 986,234, filed Oct. 22, 2001, now abandoned, which is a continuation of International Patent Application No PCT / US00 / 11272, filed Apr. 27, 2000, now expired, which claims the benefit of the priority of U.S. Provisional Patent Application No. 60 / 131,263, filed Apr. 27, 1999, now expired. Each of these applications is incorporated by reference herein in its entirety.BACKGROUND OF THE INVENTION[0002]Non-insulin-dependent diabetes mellitus (NIDDM) is a common, chronic disease that is a major cause of morbidity and mortality in industrialized societies. NIDDM affects 95% of diabetics and afflicts more than 5% of the world's population. NIDDM has a strong genetic component and is tightly linked to obesity. The disorder is characterized by severe tissue resistance to the effects of...

AI Technical Summary

Benefits of technology

[0048]Further included is a method of increasing insulin-stimulated glucose uptake by a cell. The method comprises contacting a cell expressing resistin with insulin and further contacting the cell with a resistin-reducing amount of an anti-resistin resistin compound, thereby increasing insulin-stimulated glucose uptake by the cell.

[0061]The invention additionally includes a method of increasing blood glucose levels in a mammal. The method comprises administering a effective amount of an isolated resistin polypeptide to the mammal, thereby increasing blood glucose levels in the mammal.

[0062]In addition, there is included a method of increasing blood sugar level in a mammal. The method comprises administering to the mammal an effective amount of resistin, thereby increasing blood sugar level in the mammal.

[0063]There is further included a method of increasing blood sugar level in a mammal, wherein the method comprises administering to the mammal an isolated recombinant cell transfected with an isolated nucleic acid encoding resistin wherein the nucleic acid is expressed in the cell, wherein the presence of the recombinant cells in the mammal effects an increased blood sugar level in the mammal.

Problems solved by technology

These compounds are ineffective at lowering serum glucose levels in the absence of insulin.

Chronic TZD therapy also leads to modest weight gain in rodents and humans.

However, none of these compounds binds to PPAR-γ with affinities in the nanomolar range.

Images